dc.contributor.author | Olsen, Erik | |
dc.contributor.author | Holzhauer, Björn | |
dc.contributor.author | Julius, Stevo | |
dc.contributor.author | Kjeldsen, Sverre | |
dc.contributor.author | Larstorp, Anne Cecilie Kjeldsen | |
dc.contributor.author | Mancia, Giuseppe | |
dc.contributor.author | Mehlum, Maria Hollund | |
dc.contributor.author | Mo, Rune | |
dc.contributor.author | Rostrup, Morten | |
dc.contributor.author | Søraas, Camilla Lund | |
dc.contributor.author | Zappe, Dion H. | |
dc.contributor.author | Weber, Michael A. | |
dc.date.accessioned | 2023-01-06T14:07:24Z | |
dc.date.available | 2023-01-06T14:07:24Z | |
dc.date.created | 2021-01-15T16:24:09Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 0803-7051 | |
dc.identifier.uri | https://hdl.handle.net/11250/3041643 | |
dc.description.abstract | Purpose
Available data of event-based clinical outcomes trials show that little evidence supports the guidelines recommendations to lower blood pressure (BP) to <130/80 mmHg in middle-aged and elderly people with type 2 diabetes mellitus and hypertension. We addressed this issue by post-hoc analysing the risk of cardiovascular (CV) events in mostly elderly high-risk hypertensive patients with type 2 diabetes mellitus participating in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial.
Material and methods
Patients (n = 5250) were divided into 4 groups according to the proportion of on-treatment visits before the occurrence of an event (<25% to ≥ 75%) in which BP was reduced to <140/90 or <130/80 mmHg.
Results
After adjustment for baseline demographic differences between groups, a reduction in the proportion of visits in which BP achieved <140/90 mmHg accompanied a progressive increase in the risk of CV mortality and morbidity as well as of cause-specific events such as stroke, myocardial infarction and heart failure. A progressive reduction in the proportion of visits in which BP was reduced <130/80 mmHg did not have any effect on CV risks.
Conclusion
In mostly elderly high-risk hypertensive patients with type 2 diabetes mellitus participating in the VALUE trial, achieving more frequently BP <140/90 mmHg showed a marked protective effect on overall and all cause-specific cardiovascular outcomes. This was not the case for a more frequent achievement of the more intensive BP target, i.e. <130/80 mmHg. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Taylor & Francis | en_US |
dc.title | Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus and hypertension | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | acceptedVersion | en_US |
dc.source.pagenumber | 0 | en_US |
dc.source.journal | Blood Pressure | en_US |
dc.identifier.doi | 10.1080/08037051.2020.1855968 | |
dc.identifier.cristin | 1872345 | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.fulltext | preprint | |
cristin.qualitycode | 1 | |